UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington,~~ WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 ORor 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July ~~April 26~~10, 2019

~~Scivanta~~SCIVANTA ~~Medical~~MEDICAL ~~Corporation~~CORPORATION

(Exact name of registrant as specified in ~~its~~ charter)

Nevada	000-27119	~~000~~22-~~27119~~2436721	~~22-2436721~~
(state or other jurisdiction of incorporation)		(Commission File Number)	(IRS Employer Identification Number)
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

215 Morris Avenue, Spring Lake, New Jersey 07762

606 Liberty Ave., 3^rd Floor, Pittsburgh, PA	15222
(Address of principal executive offices)	(Zip Code)

~~(address~~Registrant’s oftelephone ~~principal~~number, ~~executive offices) (zip~~including area code: (412) 851-3388

~~(732)~~215 ~~282-1620~~ Morris Avenue, Spring Lake, New Jersey, 07762

(~~registrant’s~~Former ~~telephone~~name ~~number~~or former address, ~~including~~if changed ~~area~~since ~~code~~last report)

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Emerging~~Securities ~~growth~~registered ~~company~~pursuant xto Section 12(b) of the Act:

IfTitle anof ~~emerging~~each ~~growth~~class ~~company,~~Trading ~~indicate~~Symbol(s) byName ~~check~~of ~~mark~~each ifexchange ~~the registrant~~on ~~has~~which ~~elected~~registered ~~not~~Common toStock ~~use~~SCVM ~~the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨~~OTC:Pink

~~Item~~Emerging ~~5.02~~growth ~~Departure~~company ~~of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~☒

~~On April~~If ~~26,~~an ~~2018,~~emerging ~~the~~growth ~~Board~~company, ofindicate ~~Directors~~by ofcheck ~~the~~mark ~~registrant~~if ~~accepted~~ the ~~resignation of Thomas Gifford as President and a member~~ ~~of the~~ registrant’s ~~Board of Directors and appointed Leonard Lovallo as President. Leonard Lovallo, 37, is Managing Member of Millennial Investments, LLC, a consulting firm that he controls, through which he~~ has, ~~since~~elected ~~2014,~~not ~~assisted~~to ~~public~~use ~~and private companies in~~ the ~~areas~~extended oftransition ~~mergers,~~period ~~acquisitions,~~for ~~debt~~complying ~~restructuring,~~with ~~equity~~any ~~investments~~new ~~and~~or ~~corporate~~revised ~~governance.~~financial ~~Mr.~~accounting ~~Lovallo~~standards ~~graduated~~provided ~~from~~pursuant ~~the~~to ~~State~~Section ~~University of New York~~ 13(~~Buffalo~~a) ~~with a BA in psychology. In connection with his being appointed as President~~ of the ~~registrant~~Exchange MrAct. ~~Lovallo is receiving 500,000 shares of the registrant’s common stock, an award of 1,000,000 shares upon the registrant becoming current in its SEC filings and a salary of $2,000 per month.~~ ☐

2Item 4.01 – Changes in Registrant’s Certifying Accountant

~~SIGNATURES~~Effective July 10, 2019, Scivanta Medical Corporation (“Scivanta”) dismissed its independent registered public accounting firm, Mazars USA LLP (formerly WeiserMazars LLP) (“Mazars”) and engaged BF Borgers CPA PC (“BF Borgers”), which actions were approved by Scivanta’s Board of Directors on July 10, 2019.

~~Pursuant~~Mazars was engaged toby the ~~requirements~~registrant on March 3, 2005. From the date of Mazars’ engagement through the ~~Securities~~date ~~Exchange~~of ~~Act~~resignation, (i) Scivanta had no disagreements (as that term is defined in Item 304(a)(1)(iv) of ~~1934~~Regulation S-K) with Mazars on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the ~~registrant~~satisfaction of ~~has~~Mazars, ~~duly~~would have caused ~~this~~Mazars ~~report~~to make reference to bethe ~~signed~~subject onmatter of the disagreements in connection with its ~~behalf~~report byon Scivanta’s consolidated financial statements for such years or any subsequent interim period through the ~~undersigned~~date ~~hereunto~~of ~~duly~~resignation, and ~~authorized~~(ii) there were no "reportable events" (as defined in Item 304(a)(1)(v) of Regulation S-K).

Date: April 30, 2019	Scivanta Medical Corporation
	By:	/s/ Leonard Lovallo
		Name: Leonard Lovallo
		Title: President

During the years ended October 31, 2016 and 2015, and the subsequent interim period through July 10, 2019 (the date of the new engagement), Scivanta did not consult with BF Borgers regarding (i) the application of accounting principles to a specified transaction, (ii) the type of audit opinion that might be rendered on the Scivanta's financial statements by BF Borgers in either case where written or oral advice provided by BF Borgers would be an important factor considered by us in reaching a decision as to any accounting, auditing or financial reporting issues or (iii) any other matter that was the subject of a disagreement or a reportable event (as described in Items 304(a)(1)(iv) or Item 304(a)(1)(v) of Regulation S-K, respectively).

3The audit reports of Mazars on the financial statements of the Company as of and for the years ended October 31, 2016 and 2015 did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that Mazars’ reports for the fiscal years ended October 31, 2016 and 2015 did contain an explanatory paragraph regarding their substantial doubt as to our ability to continue as a going concern, and the lack of any adjustments to the financial statements that might result from that circumstance.

Scivanta made the contents of this Current Report on Form 8-K available to Mazars and requested it to furnish a letter addressed to the SEC as to whether it agrees or disagrees with, or wishes to clarify Scivanta’s expression of its views, or containing any additional information. (A copy of Mazars’ letter to the SEC is included as Exhibit 16.1 to this Current Report on Form 8-K).

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

16.1 Letter from Mazars USA LLP dated July 10, 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SCIVANTA MEDICAL CORPORATION
	(Registrant)

	By:	/s/ Leonard Lovallo
		Leonard Lovallo
		President

Date: July 16, 2019

Filing Compare · SCIVANTA MEDICAL CORP